These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19828124)

  • 1. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.
    Chang KH; Kim MS; Hong GW; Shin YN; Kim SH
    Exp Mol Med; 2012 Jan; 44(1):52-9. PubMed ID: 22064379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody.
    Hu S; Dai H; Zhang T; Fu W; Berezov SD; Chen C; Jorissen D; Takeda H; Bethune AN
    Cancer Lett; 2015 Feb; 357(1):374-383. PubMed ID: 25434797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.
    Diaz Miqueli A; Blanco R; Garcia B; Badia T; Batista AE; Alonso R; Montero E
    Hybridoma (Larchmt); 2007 Dec; 26(6):423-31. PubMed ID: 18158788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-epidermal growth factor receptor monoclonal antibodies affecting signal transduction.
    Reins HA; Steinhilber G; Freiberg B; Anderer FA
    J Cell Biochem; 1993 Feb; 51(2):236-48. PubMed ID: 8382707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
    Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
    Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
    Sato S; Drake AW; Tsuji I; Fan J
    PLoS One; 2012; 7(12):e51964. PubMed ID: 23251664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab.
    Wang A; Cui M; Qu H; Di J; Wang Z; Xing J; Wu F; Wu W; Wang X; Shen L; Jiang B; Su X
    Oncotarget; 2016 Nov; 7(46):75293-75306. PubMed ID: 27659529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
    Pedersen MW; Jacobsen HJ; Koefoed K; Hey A; Pyke C; Haurum JS; Kragh M
    Cancer Res; 2010 Jan; 70(2):588-97. PubMed ID: 20068188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations.
    Berger C; Krengel U; Stang E; Moreno E; Madshus IH
    J Immunother; 2011 Sep; 34(7):550-5. PubMed ID: 21760527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.
    Bellone S; Frera G; Landolfi G; Romani C; Bandiera E; Tognon G; Roman JJ; Burnett AF; Pecorelli S; Santin AD
    Gynecol Oncol; 2007 Sep; 106(3):513-20. PubMed ID: 17540437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
    Chang C; Takayanagi A; Yoshida T; Shimizu N
    Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
    Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
    J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.